↓ Skip to main content

Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients

Overview of attention for article published in Frontiers in immunology, April 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients
Published in
Frontiers in immunology, April 2022
DOI 10.3389/fimmu.2022.874108
Pubmed ID
Authors

Marina Alexandre, Gérôme Bohelay, Thomas Gille, Christelle Le Roux-Villet, Isaac Soued, Florence Morin, Frédéric Caux, Sabine Grootenboer-Mignot, Catherine Prost-Squarcioni

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 2 20%
Student > Postgraduate 1 10%
Student > Ph. D. Student 1 10%
Lecturer > Senior Lecturer 1 10%
Student > Master 1 10%
Other 0 0%
Unknown 4 40%
Readers by discipline Count As %
Medicine and Dentistry 5 50%
Biochemistry, Genetics and Molecular Biology 1 10%
Unknown 4 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2022.
All research outputs
#16,048,114
of 26,166,431 outputs
Outputs from Frontiers in immunology
#15,656
of 33,003 outputs
Outputs of similar age
#220,833
of 451,130 outputs
Outputs of similar age from Frontiers in immunology
#813
of 1,694 outputs
Altmetric has tracked 26,166,431 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 33,003 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,130 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,694 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.